Analysts: No Actelion deal before PhIII macitentan data; Baxter flu vax matches conventional jab;

@FierceBiotech: Obama proposal would shorten exclusivity period. News | Follow @FierceBiotech

@JohnCFierce: Expect to see CVRs as a regular feature in M&A. | Follow @JohnCFierce 

> Seattle-based Pacific Biomarkers saw a significant jump in revenue during the first six months of its fiscal year, but the numbers still didn't pan out quite the way the company would have liked. PacBio report

> Despite all the buzz about a potential takeover of Actelion, analysts say they don't expect any bidder will make a play for the developer until they can get a clear look at late-stage data on macitentan, a potential blockbuster lung drug. Story

> Baxter International reports that its cell-based flu vaccine proved at least as effective as conventional jabs. Story

> Germany's Activaero GmbH announced that it has closed a further financing round of € 5.0 million ($ 6.8 million). Activaero release

> Halozyme Therapeutics and Roche announced that the first patient received subcutaneous  MabThera (rituximab) in a Phase III registration trial using Enhanze technology. Halozyme release

> With its Alzheimer's drug Dimebon under a cloud, Medivation has been working hard to shift investors' focus to its cancer therapy, MDV3100. Yesterday the developer announced "positive, new, long-term follow-up data" from the Phase I/II trial of MDV3100 in patients with advanced prostate cancer. Medivation release

> A microsponge crafted from seaweed has become the "dirt cheap" basis for a new tool that can snare a wide range of biomarkers, a new approach aimed at accelerating and improving the diagnosis of cancer and other diseases. Article

> A new sensor that can track a trio of proteins which are known to spike in the wake of a heart attack promises to give physicians a new and better approach to diagnosing patients and treating their condition. Article

And Finally...The CDC reports that the rate of new hepatitis C cases has dropped sharply when compared to the early '80s. Story